[Skip to Content]
[Skip to Content Landing]
Views 537
Citations 0
Review
January 3, 2019

Association Between Reimbursement Incentives and Physician Practice in Oncology: A Systematic Review

Author Affiliations
  • 1Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2Department of Health Policy and Management, University of North Carolina Gillings School of Global Public Health, Chapel Hill
  • 3Cecil G. Sheps Center for Health Services Research, Chapel Hill, North Carolina
  • 4Department of Hematology/Oncology, University of North Carolina at Chapel Hill School of Medicine
  • 5Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
  • 6Davidoff Cancer Center, Rabin Medical Center, Petach Tikvah, Israel
JAMA Oncol. Published online January 3, 2019. doi:10.1001/jamaoncol.2018.6196
Key Points

Question  Do the financial incentives within oncology reimbursement affect physicians’ practice patterns?

Findings  In this systematic review of 18 studies that evaluated physicians’ response to reimbursement incentives across various clinical settings, most studies found evidence of an association between reimbursement incentives and delivery of cancer care. The ability to self-refer for radiation oncology services was associated with increased use of radiotherapy, and greater profitability of an anticancer drug was associated with increased use of that drug.

Meaning  How oncology care is reimbursed may affect clinical care delivery.

Abstract

Importance  Significant controversy exists regarding whether physicians factor personal financial considerations into their clinical decision making. Within oncology, several reimbursement policies may incentivize physicians to increase health care use.

Objective  To evaluate whether the financial incentives presented by oncology reimbursement policies affect physician practice patterns.

Evidence Review  Studies evaluating an association between reimbursement incentives and changes in reimbursement policy on oncology care delivery were reviewed. Articles were identified systematically by searching PubMed/MEDLINE, Web of Science, Proquest Health Management, Econlit, and Business Source Premier. English-language articles focused on the US health care system that made empirical estimates of the association between a measurement of physician reimbursement/compensation and a measurement of delivery of cancer treatment services were included. The Risk of Bias in Non-Randomized Studies of Interventions tool was used to assess risk of bias. There were no date restrictions on the publications, and literature searches were finalized on February 14, 2018.

Findings  Eighteen studies were included. All were observational cohort studies, and most had a moderate risk of bias. Heterogeneity of reimbursement policies and outcomes precluded meta-analysis; therefore, a qualitative synthesis was performed. Most studies (15 of 18 [83%]) reported an association between reimbursement and care delivery consistent with physician responsiveness to financial incentives, although such an association was not identified in all studies. Findings consistently suggested that self-referral arrangements may increase use of radiotherapy and that profitability of systemic anticancer agents may affect physicians’ choice of drug. Findings were less conclusive as to whether profitability of systemic anticancer therapy affects the decision of whether to use any systemic therapy.

Conclusions and Relevance  To date, this study is the first systematic review of reimbursement policy and clinical care delivery in oncology. The findings suggest that some oncologists may, in certain circumstances, alter treatment recommendations based on personal revenue considerations. An implication of this finding is that value-based reimbursement policies may be a useful tool to better align physician incentives with patient need and increase the value of oncology care.

×